ArticlePsychopharmacology2026
GlyT1 inhibition enhances working memory in the mouse TUNL task and normalizes NMDA antagonist-induced network activity.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleWorking memory deficits are a core feature of psychiatric disorders such as schizophrenia and bipolar disorder, yet effective pharmacological strategies remain elusive. The trial unique non-matching to location (TUNL) task offers improved face validity compared to traditional maze-based tasks; however, no systemically administered compound has been shown to enhance performance in this task in naïve mice. Furthermore, the neural circuits underlying working memory impairments remain incompletely understood. Functional ultrasound (fUS) imaging was used alongside behavioral testing to provide circuit-level context for pharmacological effects on working memory.
objectivesThis study had two primary aims: (i) to assess whether an optimized TUNL task can detect both impairments and improvements in working memory in mice, and (ii) to examine behavioral and circuit-level effects of the GlyT1 inhibitor bitopertin.
methodsWe used an optimized TUNL task protocol to assess the effects of pharmacological modulation of glutamatergic and cholinergic signaling on task performance. fUS imaging was used to investigate associated neural circuit-level changes.
resultsScopolamine impaired task performance to chance levels, whereas the GlyT1 inhibitor bitopertin improved task performance and rescued deficits induced by the NMDA receptor antagonist MK-801. Performance was evaluated across different cognitive loads by varying the spatial distance between sample and non-match cues. fUS imaging revealed that bitopertin prevented ketamine-induced increases in cerebral blood volume within key working memory regions, including the prefrontal cortex, the dorsal hippocampal regions and the dorsal thalamus.
conclusionIn summary, the TUNL task is sensitive to both impairments and enhancements of working memory in mice, even in the absence of pharmacological impairment. These findings identify GlyT1 inhibition as a pharmacological strategy capable of improving working memory performance and normalizing NMDA receptor antagonist-induced network activity.
Indexed as
Identifiers
42405981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.